Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | DRD1 | P21728 | 6/20 | 0.43 |
| ▸ | DRD4 | P21917 | 6/20 | 0.43 |
| ▸ | DRD5 | P21918 | 6/20 | 0.43 |
| ▸ | DRD3 | P35462 | 6/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165187 | 0.80 | HTR2B (0.59) | DRD2DRD4DRD3HTR2B | |
| SCHEMBL6164723 | 0.80 | HTR2B (0.43) | HTR2B | |
| SCHEMBL6167382 | 0.77 | MEN1 (0.46) | HTR2B | |
| SCHEMBL6167501 | 0.77 | KMT2A (0.46) | — | |
| SCHEMBL6166994 | 0.77 | KDM4E (0.46) | — | |
| SCHEMBL6167911 | 0.76 | L3MBTL1 (0.37) | CHRM1HTR2BCHRM3 | |
| SCHEMBL27571644 | 0.75 | DRD2 (0.76) | KCNH2DRD2HTR1ADRD1DRD4 | |
| SCHEMBL15779804 | 0.75 | DRD2 (0.76) | KCNH2DRD2HTR1ADRD1DRD4 | |
| SCHEMBL6167825 | 0.75 | ALDH1A1 (0.54) | HTR2B | |
| SCHEMBL6168951 | 0.74 | HTR2B (0.51) | HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349850-B1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | SOD CONSEILS RECH APPLIC (FR) | 2005-09-07 | — | — | EP | claimed |
| EP-1349850-A1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-10-08 | — | — | EP | claimed |
| WO-2002053559-A1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-11 | — | — | WO | claimed |
| US-20040077640-A1 | Sodium channel modulators derived from 2-piperidylimidazoles | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1349850-A1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002053559-A1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077640-A1 | Sodium channel modulators derived from 2-piperidylimidazoles | KCNH1, HCN4, KCNH2 | KCNH2 3/4885DRD2 1487/4885HTR1A 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.